Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2841151 | 0.86 | RAPGEF4 (0.34) | ACHEKDM1AKDM1BRAPGEF4PTGS1 | |
| SCHEMBL12754484 | 0.80 | APEX1 (0.53) | APEX1GAACA2CA4 | |
| SCHEMBL8309828 | 0.79 | RAPGEF4 (0.40) | ACHEKDM1AKDM1BRAPGEF4PTGS1 | |
| SCHEMBL13550027 | 0.79 | GAA (0.36) | GAAKDM1AKDM1BRAPGEF4PTGS1 | |
| SCHEMBL13550024 | 0.79 | ALDH1A1 (0.33) | GAAKDM1AKDM1BRAPGEF4PTGS1 | |
| SCHEMBL24724647 | 0.75 | PTGS1 (0.38) | PTGS1PTGS2ALDH1A1 | |
| SCHEMBL15285867 | 0.75 | CYP3A4 (0.40) | ALDH1A1 | |
| SCHEMBL8773815 | 0.75 | PTGS2 (0.47) | GAAPTGS1PTGS2CA2CA4 | |
| SCHEMBL20974621 | 0.75 | GAA (0.31) | GAA | |
| SCHEMBL13550039 | 0.75 | CYP3A4 (0.37) | GAARAPGEF4ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746435-B1 | SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3746435-B1 | SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2022-08-03 | — | — | EP | disclosed |
| US-10662204-B2 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-05-26 | — | — | US | disclosed |
| WO-2019150305-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-01 | — | — | US | disclosed |
| EP-2906553-B1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-20190002454-A1 | NRF2 Regulators | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-03 | — | — | US | disclosed |
| US-10144731-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-04 | — | — | US | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20160318917-A1 | NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-2155711-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | Sanofi-Aventis (FR) | 2010-02-24 | — | — | EP | disclosed |
| US-20100010058-A1 | Azoline Compounds for Combating Arthropod Pests | BASF SE (DE) | 2010-01-14 | — | — | US | disclosed |
| CN-101360723-A | Process for preparing pyrimidinedione derivatives | TAKEDA PHARMACEUTICAL (JP) | 2009-02-04 | — | — | CN | disclosed |
| US-20080312085-A1 | Pesticidal Compositions | BASF SE (DE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312085-A1 | Pesticidal Compositions | BASF SE (DE) | 2008-12-18 | — | — | US | disclosed |
| WO-2008151211-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
| CN-101133029-A | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK & CO INC (US) | 2008-02-27 | — | — | CN | disclosed |
| WO-2007147701-A1 | AZOLINE COMPOUNDS FOR COMBATING ARTHROPOD PESTS | BASF SE (DE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007071585-A1 | PESTCIDAL COMPOSITIONS | BASF SE (DE) | 2007-06-28 | — | — | WO | disclosed |
| CN-1926128-A | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO INC (JP) | 2007-03-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002454-A1 | NRF2 Regulators | NFE2L2, KEAP1, NQO1 | APEX1 300/4885ACHE 4756/4885GAA 2667/4885 |
| US-20160318917-A1 | NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | APEX1 300/4885ACHE 4756/4885GAA 2667/4885 |
| US-20100010058-A1 | Azoline Compounds for Combating Arthropod Pests | NR0B1, NR4A1, NR4A3 | APEX1 1668/4885ACHE 605/4885GAA 4801/4885 |
| US-10662204-B2 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents | DPYD, PDXK, TYMP | APEX1 1914/4885ACHE 3532/4885GAA 841/4885 |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | DPYD, TYMP, TOP2A | APEX1 1509/4885ACHE 4336/4885GAA 763/4885 |
| US-20080312085-A1 | Pesticidal Compositions | ANXA1, PRDX1, PRDX2 | APEX1 104/4885ACHE 119/4885GAA 3202/4885 |
| US-10144731-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | APEX1 300/4885ACHE 4756/4885GAA 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.